Yonghe Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yonghe Chen has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Lei Lian
Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
9 shared publications Bin Zhong
Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
5 shared publicationsJunsheng Peng
Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
5 shared publicationsZhizhong Xiong
Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
5 shared publicationsYi Lin
Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
4 shared publicationsBochen Lai
Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
3 shared publications
Latest Publications
- 1 June 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (8) , 7382
ASO Visual Abstract: Blindly Trusting the Stage: The Therapeutic Consequences of Clinical Staging Inaccuracy in Gastric Cancer
- 1 June 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (8) , 7382
ASO Visual Abstract: Blindly Trusting the Stage: The Therapeutic Consequences of Clinical Staging Inaccuracy in Gastric Cancer
- 13 May 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (8) , 7320-7330
Blindly Trusting the Stage: The Therapeutic Consequences of Clinical Staging Inaccuracy in Gastric Cancer
This study aimed to quantify clinical staging accuracy rates and evaluated the consequences if treatment decisions were based solely on clinical stages. Th
- 13 May 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (8) , 7320-7330
Blindly Trusting the Stage: The Therapeutic Consequences of Clinical Staging Inaccuracy in Gastric Cancer
This study aimed to quantify clinical staging accuracy rates and evaluated the consequences if treatment decisions were based solely on clinical stages. Th
- 23 March 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (5) , 111767
Neoadjuvant chemotherapy for Lauren diffuse-type gastric cancer: Is it necessary?
- 23 March 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (5) , 111767
Neoadjuvant chemotherapy for Lauren diffuse-type gastric cancer: Is it necessary?
- Open Access
- 12 February 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (4) , 111279
Landscape of splicing factors in early-onset gastric cancer reveals SRSF1 as a key driver of oxaliplatin resistance
- 12 February 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (4) , 111279
Open AccessLandscape of splicing factors in early-onset gastric cancer reveals SRSF1 as a key driver of oxaliplatin resistance
- Open Access
- 28 November 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1834
Unsupervised machine learning reveals prognostic value of dynamic carbohydrate antigen 125 trajectory in gastric cancer
Carbohydrate Antigen 125 (CA125), a tumor-associated glycoprotein, is an established prognostic marker in gastric cancer. However, the trajectory of CA125
- 28 November 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1834
Open AccessUnsupervised machine learning reveals prognostic value of dynamic carbohydrate antigen 125 trajectory in gastric cancer
Carbohydrate Antigen 125 (CA125), a tumor-associated glycoprotein, is an established prognostic marker in gastric cancer. However, the trajectory of CA125
- Open Access
- 21 October 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15
Integrating computed tomography and biopsy images to predict chemotherapy response in gastric cancer
Aims: To predict pathological complete response to neoadjuvant chemotherapy in advanced gastric cancer by integrating multimodal radiomic and pathomic data.Methods: Eligible patients with advanced gastric cancer underwent neoadjuvant chemotherapy followed by radical gastrectomy. We collected pre-treatment venous-phase computed tomography (CT) scans and whole-slide H&E-stained gastroscopic biopsy sections for feature extraction. Three models were constructed: a unimodal radiomic model, a unimodal pathomic model, and a multimodal model combining both feature types. Model performance was evaluated using the area under the curve (AUC).Findings: Our study included 295 AGC patients who received NAC and radical surgery between February 2013 and September 2022 (236 in the training cohort, 59 in the validation cohort). A total of 42 patients (14.2%) achieved pCR. We extracted 615 radiomic and 548 pathomic features. The unimodal radiomic model (10 selected features) achieved an AUC of 0.672, while the pathomic model (13 selected features) achieved an AUC of 0.806. The multimodal model, constructed with 22 features (12 radiomic, 10 pathomic), achieved the highest AUC of 0.814. Decision curve analysis confirmed the multimodal model’s superior predictive efficacy compared to the unimodal models, highlighting the synergistic potential of combining radiomic and pathomic features.Conclusion: By integrating pathological images and CT features, we can maximize the utilization of pre-treatment information and enhance the accuracy of NAC prediction in AGC.
- 21 October 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15
Open AccessIntegrating computed tomography and biopsy images to predict chemotherapy response in gastric cancer
Aims: To predict pathological complete response to neoadjuvant chemotherapy in advanced gastric cancer by integrating multimodal radiomic and pathomic data.Methods: Eligible patients with advanced gastric cancer underwent neoadjuvant chemotherapy followed by radical gastrectomy. We collected pre-treatment venous-phase computed tomography (CT) scans and whole-slide H&E-stained gastroscopic biopsy sections for feature extraction. Three models were constructed: a unimodal radiomic model, a unimodal pathomic model, and a multimodal model combining both feature types. Model performance was evaluated using the area under the curve (AUC).Findings: Our study included 295 AGC patients who received NAC and radical surgery between February 2013 and September 2022 (236 in the training cohort, 59 in the validation cohort). A total of 42 patients (14.2%) achieved pCR. We extracted 615 radiomic and 548 pathomic features. The unimodal radiomic model (10 selected features) achieved an AUC of 0.672, while the pathomic model (13 selected features) achieved an AUC of 0.806. The multimodal model, constructed with 22 features (12 radiomic, 10 pathomic), achieved the highest AUC of 0.814. Decision curve analysis confirmed the multimodal model’s superior predictive efficacy compared to the unimodal models, highlighting the synergistic potential of combining radiomic and pathomic features.Conclusion: By integrating pathological images and CT features, we can maximize the utilization of pre-treatment information and enhance the accuracy of NAC prediction in AGC.
- 22 August 2025
- Published by Elsevier in European Journal of Radiology
- Vol. 192, 112378
Predictive model based on mesorectal fat radiomics for pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
- 22 August 2025
- Published by Elsevier in European Journal of Radiology
- Vol. 192, 112378
Predictive model based on mesorectal fat radiomics for pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
- Open Access
- 26 July 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-11
Machine learning-based dynamic CEA trajectory and prognosis in gastric cancer
Static carcinoembryonic antigen (CEA) levels are well‑established prognostic markers in patients with gastric cancer, but the significance of their dynamic trajectories over time has rarely been reported. We analysed the perioperative CEA levels (presurgery, early postsurgery, and late postsurgery) of 578 gastric cancer patients who underwent curative resection, with a median follow-up of 29 months. We used the entire cohort for k-means clustering. Survival differences between clusters were assessed using Kaplan–Meier analysis and Cox regression. Of the 578 patients, 15.57% exhibited elevated CEA levels before surgery (median 2.07 ng/mL), which then decreased to 3.29% (median 1.74 ng/mL) after surgery. However, after six months, a slight rebound was observed (18.51% elevated, median 2.98 ng/mL). K-means clustering identified three CEA trajectories: high, medium, and low (Calinski–Harabasz index: 358). Survival analysis demonstrated that higher CEA trajectories were associated with worse disease-free survival (DFS) and overall survival (OS). With the low cluster as a reference, multivariate Cox regression analysis revealed that a higher CEA trajectory was an independent prognostic factor, with an elevated risk in the high cluster (HR 2.64, 95% CI: 1.37-5.0), indicating that the high cluster had more than twice the mortality risk of the low cluster and that the medium cluster had a moderately increased mortality risk (HR 1.69, 95% CI: 1.0-2.85). Higher CEA trajectories are associated with a worse prognosis, highlighting the importance of enhanced monitoring for this group of patients. A machine learning-powered trajectory clustering algorithm employed. The trajectory cluster classification demonstrates a strong correlation with both disease-free survival and overall survival.
- 26 July 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-11
Open AccessMachine learning-based dynamic CEA trajectory and prognosis in gastric cancer
Static carcinoembryonic antigen (CEA) levels are well‑established prognostic markers in patients with gastric cancer, but the significance of their dynamic trajectories over time has rarely been reported. We analysed the perioperative CEA levels (presurgery, early postsurgery, and late postsurgery) of 578 gastric cancer patients who underwent curative resection, with a median follow-up of 29 months. We used the entire cohort for k-means clustering. Survival differences between clusters were assessed using Kaplan–Meier analysis and Cox regression. Of the 578 patients, 15.57% exhibited elevated CEA levels before surgery (median 2.07 ng/mL), which then decreased to 3.29% (median 1.74 ng/mL) after surgery. However, after six months, a slight rebound was observed (18.51% elevated, median 2.98 ng/mL). K-means clustering identified three CEA trajectories: high, medium, and low (Calinski–Harabasz index: 358). Survival analysis demonstrated that higher CEA trajectories were associated with worse disease-free survival (DFS) and overall survival (OS). With the low cluster as a reference, multivariate Cox regression analysis revealed that a higher CEA trajectory was an independent prognostic factor, with an elevated risk in the high cluster (HR 2.64, 95% CI: 1.37-5.0), indicating that the high cluster had more than twice the mortality risk of the low cluster and that the medium cluster had a moderately increased mortality risk (HR 1.69, 95% CI: 1.0-2.85). Higher CEA trajectories are associated with a worse prognosis, highlighting the importance of enhanced monitoring for this group of patients. A machine learning-powered trajectory clustering algorithm employed. The trajectory cluster classification demonstrates a strong correlation with both disease-free survival and overall survival.
- Open Access
- 1 June 2025
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 16 (3) , 823-839
CDK12 inhibition enhances oxaliplatin efficacy in gastric cancer by suppressing the MAPK signaling pathway
Background: Gastric cancer (GC) is a leading cause of cancer-related mortality worldwide. Oxaliplatin (OXA) based therapy plus/minus targeted therapy and immune check point inhibitors is the standard first-line treatment for advanced GC; however, its clinical efficacy is often hindered by the development of drug resistance. Cyclin-dependent kinase 12 (CDK12), a transcriptional regulator linked to DNA repair, plays a crucial role in transcription, cancer progression as well as drug resistance, where its exact role is unclear. In this study, we will investigate the role of CDK12 in GC progression and its potential as a therapeutic target specifically to enhance the efficacy of OXA. Methods: CDK12 expression in GC tissues was analyzed by quantitative polymerase chain reaction (qPCR) and tissue microarrays (TMAs). A Kaplan-Meier survival analysis was conducted to assess the relationship between CDK12 levels and clinical outcomes. The effect of the CDK12 inhibitor combined with OXA was evaluated through in vivo and in vitro models. RNA-sequencing and western blots were used to investigate the molecular mechanisms of CDK12 inhibitor sensitizing OXA. Results: CDK12 exhibited significant amplification frequency in GC. The Mendelian-randomization analysis revealed a positive causal association between elevated CDK12 expression and an increased risk of GC. Additionally, CDK12 was significantly overexpressed in GC tissues compared with adjacent normal tissues, and its high expression was significantly associated with a worse prognosis. The functional assays revealed that combining the CDK12 inhibitor THZ531 with OXA synergistically suppressed GC cell proliferation, induced apoptosis, and reduced colony formation in vitro, while substantially inhibiting tumor growth in xenograft models. Mechanistically, CDK12 inhibition disrupted MAPK signaling, leading to enhanced OXA-induced DNA damage and potentiated anti-tumor effects. Conclusions: Our findings suggest that CDK12 inhibition may represent a promising strategy for overcoming OXA resistance and improving GC treatment outcomes.
- 1 June 2025
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 16 (3) , 823-839
Open AccessCDK12 inhibition enhances oxaliplatin efficacy in gastric cancer by suppressing the MAPK signaling pathway
Background: Gastric cancer (GC) is a leading cause of cancer-related mortality worldwide. Oxaliplatin (OXA) based therapy plus/minus targeted therapy and immune check point inhibitors is the standard first-line treatment for advanced GC; however, its clinical efficacy is often hindered by the development of drug resistance. Cyclin-dependent kinase 12 (CDK12), a transcriptional regulator linked to DNA repair, plays a crucial role in transcription, cancer progression as well as drug resistance, where its exact role is unclear. In this study, we will investigate the role of CDK12 in GC progression and its potential as a therapeutic target specifically to enhance the efficacy of OXA. Methods: CDK12 expression in GC tissues was analyzed by quantitative polymerase chain reaction (qPCR) and tissue microarrays (TMAs). A Kaplan-Meier survival analysis was conducted to assess the relationship between CDK12 levels and clinical outcomes. The effect of the CDK12 inhibitor combined with OXA was evaluated through in vivo and in vitro models. RNA-sequencing and western blots were used to investigate the molecular mechanisms of CDK12 inhibitor sensitizing OXA. Results: CDK12 exhibited significant amplification frequency in GC. The Mendelian-randomization analysis revealed a positive causal association between elevated CDK12 expression and an increased risk of GC. Additionally, CDK12 was significantly overexpressed in GC tissues compared with adjacent normal tissues, and its high expression was significantly associated with a worse prognosis. The functional assays revealed that combining the CDK12 inhibitor THZ531 with OXA synergistically suppressed GC cell proliferation, induced apoptosis, and reduced colony formation in vitro, while substantially inhibiting tumor growth in xenograft models. Mechanistically, CDK12 inhibition disrupted MAPK signaling, leading to enhanced OXA-induced DNA damage and potentiated anti-tumor effects. Conclusions: Our findings suggest that CDK12 inhibition may represent a promising strategy for overcoming OXA resistance and improving GC treatment outcomes.